2024 Highlight Review Newsletter - Posters, Publications & Presentations
Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy
March (Preclinical) Song, P Lynch ,S DeMellier, C et al. Abstract 1120: CD8 ImmunoPET imaging identifies an immunogenically active tumor microenvironment following radiotherapy in primary TNBC. Cancer Res 15 March 2024; 84 (6_Supplement): 1120. https://doi.org/10.1158/1538-7445.AM2024-1120
April CD8 ImmunoPET™ imaging identifies an immunogenically active tumor microenvironment following radiotherapy in primary TNBD (preclinical)
May Amaral T, Kneilling M, Forschner A, et al. Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitors by investigation of CD8+ immune infiltrate with [89Zr] crefmirlimab berdoxam PET.
June Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitors by investigation of CD8+ immune infiltrate with [89Zr] crefmirlimab berdoxam
The Scientific and Clinical Potentials of Imaging Cytotoxic T-Cells Using Zr-89 Crefmirlimab Berdoxam (awarded 1st place in the Educational Exhibits Section)
Prompt Attention Convolution Net (PAC-NET) for Low-Count Zr-89 Immuno-PET Denoising (awarded 2nd place in the Physics, Instrumentation & Data Sciences section)
August Peeters, E, van Genugten E, Timmermans, S et al. [89Zr]Zr-crefmirlimab berdoxam PET imaging to assess CD8+ T-cell compartmentalization (presented at TOPIM August 2024)
December Bria-IMT CD8+ Tumor Infiltrating Lymphocytes Turn "Cold" Tumor "Hot" in Metastatic Breast Cancer
Publications Theranostics CD8 ImmunoPET™ imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models (preclinical)
Frontiers in Medicine Preliminary evidence of localizing CD8+ T-cell responses in COVID-19 patients with PET imaging.
Breast Cancer Research Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4+ and CD8+ cells (preclinical)
